Skip to main
UNCY

Unicycive Therapeutics (UNCY) Stock Forecast & Price Target

Unicycive Therapeutics (UNCY) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Unicycive Therapeutics Inc. is poised for positive growth due to the advancement of its key product candidates, oxylanthanum carbonate (OLC) and UNI-494, addressing significant unmet medical needs in kidney disease treatment. The company is confident in its ability to navigate the commercialization pathway for OLC, particularly following corrective measures taken by its third-party manufacturing vendor and active dialogue with key payers for reimbursement strategies. Despite the adjustments in share count and operational expenditures, the raised price target reflects strong market potential, indicating investor confidence in Unicycive's strategic execution and anticipated product launches.

Bears say

Unicycive Therapeutics Inc faces significant risks that could adversely impact its market valuation, including potential delays in the market launch of its product candidate oxylanthanum carbonate (OLC) and challenges related to reimbursement and commercial execution. The company's current valuation of $83 million appears at risk, particularly as they project potential revenues of $625 million by 2031, which may be overly optimistic given the hurdles anticipated in their product development and market strategy. Additionally, concerns over dilution due to the exercise of stock options and milestones could also hinder investor confidence and limit stock price appreciation.

Unicycive Therapeutics (UNCY) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Unicycive Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Unicycive Therapeutics (UNCY) Forecast

Analysts have given Unicycive Therapeutics (UNCY) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Unicycive Therapeutics (UNCY) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Unicycive Therapeutics (UNCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.